Articles On Prescient Therapeutics (ASX:PTX)

Prescient Therapeutics (ASX:PTX) has jumped +15% as EU drug regulator European Medicines Agency awarded orphan drug designation (ODD) – effectively an early-stage fast-track status for regulatory efforts – to Prescient’s flagship product PT...

Two dozen esteemed sector figures recently gathered over lunch to recount their career highs and lows One luminary recalls an uncomfortable close encounter with a drug cartel, while others overcame the impact of academic and corporate frau...

Perversely, Polynovo stands to benefit from a US reimbursement cut for outpatients ASX biotechs had a poor August, but they will Spring into action Race Oncology opens Hong Kong site in “cautious” trial rollout   PolyNovo (ASX:PNV) shares...

Highlights US policy changes back research on rare diseases Australian biotech firms gain momentum New regulatory clarity benefits orphan drug development Australian biotech companies focused on rare disease therapies are gaining...

The ASX200 has traded lower on the eve of close, continuing the bourse’s up and down week. IT, Discretionary and Health Care were the best performing sectors approaching close. The Materials sector was hammered and was down more than...

Investors back Prescient with applications for $3m placement Brings total funds raised from the placement and recent SPP to $9.8m The company will use the funds to support its cancer treatment   Special Report: Prescient Therapeutics h...

 Plenty of biotechs are lodging late in the piece, but without too many ‘dog ate my homework’ excuses Telehealth group looks to post-pandemic recovery   Botanix, Amplia and Vitrafy pass muster with the brokers   Some students hand in thei...

Highlights Prescient Therapeutics completes share purchase plan to advance oncology pipeline Interim funding supported by follow-on placement to sophisticated participants Company focuses on progressing PTX-100 through clini...

Energy stocks climb as oil ticks up 2pc ASX rallies late to climb 0.08pc Gold stocks slide despite recovering gold price   ASX lifts as clouds part for energy sector The ASX was in a decidedly bad mood today, hanging out in negative terri...

Prescient at critical stage of development with phase 2a trial underway for PTX-100 PTX-100 granted orphan drug and fast track designations by the US FDA, unlocking benefits Focus on advancing PTX-100 to potential registrational phase 2b t...

Highlights Breaks down biotech company stages from discovery to commercialisation Explores real-world examples of ASX-listed biotech companies Offers insight into navigating risk across drug development phases Biotech investing is...

Prescient Therapeutics (ASX: PTX) is fast emerging as the newest developer of an advanced cancer drug to meet a significant market need, potentially converting years of work into billions of dollars. The company’s lead candidate PTX-100 is...

It’s no secret that the rate of cancer both in Australia and overseas appears to be increasing – particularly among young people.  Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from th...

It’s no secret that the rate of cancer both in Australia, and overseas, appears to be increasing – particularly among young people.  While part of the story is an increased ability to diagnose cancers early thanks to technological advanc...

Pitt Street Research updates valuation for Prescient Therapeutics, one of the most advanced oncology companies on ASX Prescient has kicked off a phase 2a trial of PTX-100 in patients with a rare blood cancer Pitt Street says PTX-100 could...

Oncology biotech Prescient Therapeutics (ASX: PTX) has announced the completion of its first US site visit for its Phase 2a trial of PTX-100 for patients with refractory or relapsed cutaneous T-cell lymphoma (r/r CTCL). The Massey Comprehen...

ASX beats hasty retreat from new record high, down 0.79pc Info tech rises against the tide, adding 0.85pc Banks and financial stocks struggle alongside materials sector, leading losses Info tech fires up despite dour market The ASX unwoun...

Stockhead’s Tylah Tully catches up with Prescient Therapeutics (ASX:PTX) CEO James McDonnell after the company hit a major milestone with the initiation of its first US site for the Phase 2a trial of PTX-100. McDonnell also discusses the pr...

Highlights AuKing Mining commences exploration at Myoff Creek project in British Columbia Project focuses on niobium and rare earth elements in a key mining jurisdiction Activity supports ongoing interest in small-cap resour...

Prescient Therapeutics is focused on development of lead compound PTX-100 to treat rare blood cancer New leadership to steer the company through next stage of clinical program First patient dosed in phase 2a trial with PTX-100 granted US F...

Highlights Novo Resources identifies high-grade gold intercepts at Tibooburra Gold Project in NSW Orthocell reports record FY2025 revenue, advancing regenerative medicine footprint Resolution Minerals gears up for major dril...

POTUS threatens a foreign drug tariff, but gives Big Pharma more time to shift production onshore ASX drug makers say they won’t be overly affected by any Trump tariff whack Island Pharma acquires a secondary virus program   Donald Trump...

ASX biotechs target global cell therapy market, projected to reach ~US$48bn by 2034 Arovella the only ASX-listed biotech delving into CAR iNKT therapies and one of few globally Chimeric aims to ‘break new ground’ in treatment of solid tumo...

What is Relapsed or Refractory T-Cell Lymphoma? Why is it so difficult to treat? What therapies currently exist? And what changes can the healthcare sector make in this area? Tylah Tully is joined in this episode by Prescient Therapeutics (...

Clinical-stage oncology company Prescient Therapeutics (ASX: PTX) is looking to disrupt a US$1.8 billion market on the back of outstanding Phase 1b clinical trial data for lead candidate PTX-100 to treat cutaneous T-cell lymphoma (CTCL). No...

Vital Signs is a podcast series focused on investing, hosted by Senior Health and Biotech journalist Nadine McGrath. In this episode, Nadine chats with Prescient Therapeutics (ASX:PTX) CEO James McDonnell. Prescient is focused on developin...

Highlights Lithium Universe advances with key acquisition in photovoltaic recycling technology. Surefire Resources intersects sulphides at Yidby Gold Project. St George Mining begins new geophysical work at Brazilian rare ea...

  Prescient is focused on developing new therapies for cancers of unmet need Lead compound PTX-100 is in a Phase II trial to treat rare blood cancer Strong US FDA support for PTX-100, including orphan drug and fast-track designations   Sp...

In this HotCopper Capital Compass interview, Prescient Therapeutics (ASX:PTX) CEO James McDonnell discusses the company’s progress with PTX-100, a first-in-class therapy targeting the RAS pathway in cancer. Listen to the HotCopper podcas...

First patient dosed in Prescient’s Phase 2a trial of PTX 100 in patients with relapsed or refractory cutaneous T-cell lymphoma Dosing marks a key milestone in development of PTX-100 as a potential treatment for the rare cancer Phase 2a tri...

Highlights  ASX200 futures point to a modestly stronger start.  Uranium stocks gain momentum on new US policy.  European markets rally as US and UK take holidays.  Australian shares look set for a slightly positive open as ASX200...

Arovella is one of only a handful of biotechs pursuing CAR-iNKT immunotherapies – and is the only ASX-listed exemplar The “soldiers of the blood stream”, CAR-iNKT cells offer potential advantages including easier off-the-shelf therapies Th...

Highlights: The ASX starts the day with minimal movement, reflecting uncertainty in early trading. Pharma and semiconductor tariff discussions weigh on global markets, while the US faces a downward trend. ASX stocks like Neu...

Highlights: Healthcare and financials lifted the ASX 200 despite global trade disruptions. US markets ended lower following renewed tariff concerns affecting semiconductor and pharmaceutical sectors. Small-cap activity remai...

Prescient Therapeutics (ASX: PTX) has received fast-track designation from the US Food and Drug Administration for lead candidate PTX-100 to treat adults with relapsed or refractory mycosis fungoides. The skin condition – a type of blood ca...

Highlights: Galan Lithium (ASX:GLN) secures funding for advancing production at its Argentina-based lithium project. Ordell Minerals (ASX:ORD) completes drilling activities at Barimaia Gold Project with final assay results in han...

The ASX has been up 0.22% higher at 7,778 points in morning trades. Galan Lithium (ASX:GLN) has been among the most watched on HotCopper forums today after the company landed a binding funding package to complete construction activities...

Morning, and welcome to Stockhead’s Top 10 (at 11… ish), highlighting the movers and shakers on the ASX in early-doors trading. With the market opening at 10am sharp eastern time, the data is taken at 10:15, once trading kicks off in earnes...

It’s up and go time for LTR in the US market All the budget healthcare news – and it’s a short item Prescient launches phase 2a study for a rare blood cancer   The developer of a nasal spray-mist erectile dysfunction (ED) treatment, LTR P...

Highlights  ASX 200 fluctuates as global trade concerns persist.  Gold prices surge to record highs, boosting mining stocks.  Mixed movements in US markets amid Federal Reserve comments.  The Australian share market showed signs o...

The ASX has renewed its Santa rally closing with strong gains  Financials/banks raked it in, on the whole, with all sectors in the green News Corp’s blockbuster Foxtel deal with DAZN turned heads; Bitcoin… meh   Investors have seemingly b...

 Percheron’s Duchenne muscular dystrophy trial has been a compete flop Canaccord Genuity says Opthea shares are worth at least double their current price Neurizon asks US regulator for motor neurone disease trial go-ahead   Firstly, full...

Highlights    Enhanced understanding of SCLC subtypes drives tailored treatment approaches.   Immunotherapy and antibody-drug conjugates emerge as key strategies.   Asia-Pacific region identified as a critical area for further clinica...

Alive and Kicking is renowned biotech journo Tim Boreham’s new daily wrap covering morning movers and shakers of note in the ASX Healthcare sector, Monday through Thursday.   Prescient Therapeutics chief Steve Yatomi-Clarke resigns to hea...

Cynata Therapeutics flags three trial results in the short term for three different conditions, including diabetic leg ulcers Prescient Therapeutics prepares for a blood cancer trial and potential fast-track approval Pacific Edge chairman...

Highlights PTX-100 Phase 1b trial in r/r TCL has been completed with encouraging results. Phase 2 registration trial is under planning phase. PTX-100 has been granted US Orphan Drug designation by US FDA in all TCLs. PTX-100 of Pr...

Highlights Prescient Therapeutics has received AU$2.4 million as R&D Tax Incentive rebate for FY23. R&D Tax Incentive is given under a government program providing firms cash refunds of up to 43.5% of eligible R&D expenses....

Highlights PTX is advancing its diversified pipeline of cancer therapies, backed by a world-class research, clinical and commercial team. PTX-100 Phase 1b trial data is expected in December 2023. Pre-clinical data of CellPryme surpass...

‘Big pay day’ for Prescient Therapeutics, says Pitt Street Aerometrex to benefit from the seismic shifts of Artificial Intelligence   Pitt Street Research has sent us its thesis on biotech stock, Prescient Therapeutics (ASX:PTX), with a v...